Aytu Biopharma (AYTU) EBIAT (2016 - 2025)
Aytu Biopharma (AYTU) has disclosed EBIAT for 15 consecutive years, with -$10.6 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT fell 1691.58% to -$10.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$24.9 million, a 1114.22% decrease, with the full-year FY2025 number at -$14.2 million, down 13.27% from a year prior.
- EBIAT was -$10.6 million for Q4 2025 at Aytu Biopharma, down from $2.0 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $4.0 million in Q1 2025 to a low of -$53.3 million in Q1 2022.
- A 5-year average of -$9.5 million and a median of -$6.7 million in 2022 define the central range for EBIAT.
- Peak YoY movement for EBIAT: soared 402.27% in 2024, then crashed 1691.58% in 2025.
- Aytu Biopharma's EBIAT stood at -$11.5 million in 2021, then skyrocketed by 42.04% to -$6.7 million in 2022, then surged by 96.71% to -$220000.0 in 2023, then skyrocketed by 402.27% to $665000.0 in 2024, then plummeted by 1691.58% to -$10.6 million in 2025.
- Per Business Quant, the three most recent readings for AYTU's EBIAT are -$10.6 million (Q4 2025), $2.0 million (Q3 2025), and -$20.3 million (Q2 2025).